UFP Technologies, Inc. UFPT R2K
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 19.4% over 5 years.
- Profit CAGR of 17.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UFPT UFP Technologies, Inc. R2K | 220.10 | 25.07 | $1.70B | - | 15.91% | 17.17% | 19.44% | 17.80% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.75M | 100.04M | 100.78M | 101.50M | 105.01M | 110.18M | 145.16M | 144.07M | 148.15M | 151.18M | 154.56M | 148.91M | 154.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 106.00M | 107.63M | 111.81M | 106.95M | 109.84M |
| Gross Profit | 10.29M | 8.45M | 8.18M | 9.52M | 9.94M | 8.19M | 7.84M | 10.19M | 12.99M | 12.43M | 12.71M | 12.50M | 14.37M | 13.32M | 13.77M | 12.82M | 9.95M | 10.53M | 11.38M | 12.61M | 13.41M | 12.02M | 13.07M | 17.13M | 24.32M | 25.52M | 23.28M | 28.70M | 29.64M | 27.75M | 26.13M | 30.08M | 33.03M | 41.52M | 42.06M | 42.15M | 43.54M | 42.75M | 41.97M | 44.36M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.73M | 18.68M | 19.07M | 20.96M | 21.02M |
| Operating Income | 4.19M | 4.08M | - | 3.21M | 3.93M | 2.50M | - | 2.56M | 5.67M | 5.88M | - | 5.25M | 6.57M | 6.14M | - | 5.08M | 2.99M | 3.73M | - | 5.30M | 6.21M | 5.08M | - | 6.36M | 12.20M | 25.96M | - | 12.84M | 17.04M | 15.04M | - | 15.92M | 17.95M | 24.76M | - | 23.43M | 24.86M | 23.68M | 21.00M | 23.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.72M | 29.02M | 28.33M | 26.40M | 28.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.81M | 2.67M | 2.39M | 1.93M | 1.74M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.28M | 21.63M | 21.06M | 19.54M | 21.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.10M | 4.45M | 4.68M | 1.98M | 4.11M |
| Net Income | 2.73M | 2.67M | - | 2.17M | 2.63M | 1.70M | - | 1.78M | 3.99M | 4.13M | - | 3.73M | 4.60M | 5.64M | - | 3.89M | 2.32M | 2.99M | - | 4.16M | 4.71M | 3.79M | - | 4.86M | 8.93M | 19.54M | - | 9.74M | 11.88M | 11.69M | 11.61M | 12.69M | 13.55M | 16.36M | 16.38M | 17.18M | 17.18M | 16.38M | 17.57M | 17.50M |
| Diluted EPS | 0.38 | 0.37 | 0.20 | 0.30 | 0.36 | 0.23 | 0.37 | 0.24 | 0.54 | 0.56 | 0.59 | 0.00 | 0.62 | 0.75 | 0.77 | 0.52 | 0.31 | 0.40 | 0.55 | 0.55 | 0.62 | 0.50 | 0.42 | 0.64 | 1.17 | 2.56 | 1.10 | 1.27 | 1.55 | 1.52 | 1.51 | 1.64 | 1.75 | 2.11 | 2.10 | 2.21 | 2.21 | 2.11 | 2.25 | 2.24 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 353.79M | 400.07M | 504.42M | 602.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 263.53M | 287.85M | 357.73M | 432.39M |
| Gross Profit | 26.72M | 34.62M | 36.24M | 38.32M | 41.01M | 36.88M | 37.45M | 34.65M | 35.49M | 48.31M | 53.96M | 44.68M | - | 90.26M | 112.22M | 146.69M | 170.41M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.80M | 50.89M | 62.22M | 77.44M |
| Operating Income | 8.19M | 14.39M | 15.72M | 16.67M | 17.40M | 11.56M | 11.71M | 12.24M | 11.69M | 19.61M | 24.71M | 16.73M | - | 44.46M | 61.34M | 84.47M | 92.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.37M | 68.95M | 95.80M | 111.47M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.76M | 3.65M | 8.06M | 9.80M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.72M | 53.90M | 73.03M | 82.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.93M | 8.98M | 14.04M | 14.20M |
| Net Income | - | - | - | - | 11.28M | 7.56M | 7.59M | 7.97M | 9.21M | 14.31M | 19.75M | 13.37M | - | 41.79M | 44.92M | 58.98M | 68.31M |
| Diluted EPS | 0.94 | 1.37 | 1.48 | 1.55 | 1.59 | 1.05 | 1.05 | 1.10 | 1.26 | 1.93 | 2.63 | 1.77 | - | 5.45 | 5.83 | 7.58 | 8.75 |
| R&D Expense | - | 900.00K | 1.20M | 1.30M | 1.20M | 1.40M | 1.30M | 1.30M | 5.00M | 10.50M | 8.80M | 8.20M | 8.50M | 9.30M | 7.20M | 10.40M | 8.60M |
Compounded Sales Growth
| 5 Years: | 19.44% |
| 1 Year: | 4.10% |
Compounded Profit Growth
| 5 Years: | 17.80% |
| 1 Year: | 1.40% |
Stock Price Performance
| 1 Year: | -6.02% |
| 6 Months: | -4.20% |
| 3 Months: | +4.52% |
| 1 Month: | +18.68% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 69.48M | 79.72M | 98.62M | 104.91M | 112.55M | 119.64M | 127.93M | 138.21M | 189.60M | 188.76M | 203.20M | - | 378.19M | 404.14M | 629.00M | 655.08M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 116.35M | 144.63M | 194.94M | 201.00M |
| Cash & Equivalents | 5.14M | 13.40M | 22.10M | 29.85M | 33.48M | 37.30M | 34.05M | 29.80M | 31.36M | 37.98M | 3.24M | 3.74M | 24.23M | - | 4.45M | 5.26M | 13.45M | 20.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.54M | 70.19M | 87.54M | 86.86M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.12M | 64.45M | 84.68M | 82.91M |
| Total Liabilities | - | - | 19.25M | 17.74M | 25.36M | 19.32M | 17.56M | 16.06M | 14.88M | 14.49M | 49.14M | 26.77M | 26.31M | - | 140.65M | 118.05M | 286.24M | 231.20M |
| Current Liabilities | - | - | 10.17M | 9.47M | 13.23M | 12.32M | 11.61M | 10.67M | 9.56M | 9.94M | 20.66M | 16.78M | 15.14M | - | 55.96M | 58.21M | 76.30M | 74.86M |
| Long Term Debt | - | - | 6.85M | 5.64M | 8.31M | 2.87M | 1.87M | 859.00K | - | - | 22.29M | - | 0 | - | 51.00M | 28.00M | 176.88M | 122.95M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 68.37M | 46.04M | 206.03M | 154.48M |
| Total Equity | - | - | 49.70M | 61.31M | 73.26M | 85.59M | 94.99M | 103.57M | 113.05M | 123.71M | 140.46M | 161.99M | 176.89M | - | 237.54M | 286.09M | 342.76M | 423.88M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.61M | 7.67M | 7.71M | 7.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | 12.52M | 9.31M | 17.47M | 21.32M | 31.23M | 25.04M | - | 17.74M | 41.33M | 66.59M | 91.91M |
| Investing Cash Flow | - | - | - | - | - | - | -15.69M | -7.19M | -10.38M | -82.33M | -5.77M | -4.26M | - | 1.29M | -10.49M | -210.16M | -27.60M |
| Financing Cash Flow | - | - | - | - | - | - | -1.08M | -559.00K | -475.00K | 26.27M | -24.95M | -285.00K | - | -25.89M | -30.02M | 152.39M | -58.16M |
| Capital Expenditure | -1.86M | -3.29M | -3.74M | -11.99M | -5.83M | -13.44M | -15.74M | -7.21M | -10.38M | -5.43M | -5.78M | -4.37M | - | -13.78M | -10.49M | -9.66M | -12.93M |
| Free Cash Flow | - | - | - | - | - | - | -3.22M | 2.10M | 7.09M | 15.89M | 25.45M | 20.67M | - | 3.96M | 30.84M | 56.94M | 78.98M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.86M | 822.00K | 8.82M | 6.15M |
| Share Buybacks | - | - | - | - | - | - | 587.00K | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.5% | 28.1% | 29.1% | 28.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.6% | 15.3% | 16.7% | 15.4% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.8% | 11.2% | 11.7% | 11.3% |
| ROE % | - | - | - | - | 13.2% | 8.0% | 7.3% | 7.0% | 7.4% | 10.2% | 12.2% | 7.6% | - | 17.6% | 15.7% | 17.2% | 16.1% |
| ROCE % | - | 24.3% | 22.4% | 19.5% | 18.8% | 11.5% | 10.8% | 10.3% | 9.1% | 11.6% | 14.4% | 8.9% | - | 13.8% | 17.7% | 15.3% | 16.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.18% | 1.10M | $241.49M |
| 2 | Wasatch Advisors LP | 10.05% | 777.31K | $171.09M |
| 3 | Congress Asset Management Co | 6.77% | 523.44K | $115.21M |
| 4 | Vanguard Capital Management LLC | 4.22% | 326.73K | $71.91M |
| 5 | Boston Trust Walden Corporation | 4.10% | 317.07K | $69.79M |
| 6 | State Street Corporation | 3.92% | 303.31K | $66.76M |
| 7 | Neuberger Berman Group, LLC | 3.89% | 300.59K | $66.16M |
| 8 | Price (T.Rowe) Associates Inc | 3.19% | 246.50K | $54.26M |
| 9 | Thrivent Financial For Lutherans | 3.07% | 237.28K | $52.22M |
| 10 | Massachusetts Financial Services Co. | 2.94% | 227.30K | $50.03M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UFPT